[go: up one dir, main page]

UY37580A - Compuestos novedosos que inhiben la actividad de cinasa lrrk2 - Google Patents

Compuestos novedosos que inhiben la actividad de cinasa lrrk2

Info

Publication number
UY37580A
UY37580A UY0001037580A UY37580A UY37580A UY 37580 A UY37580 A UY 37580A UY 0001037580 A UY0001037580 A UY 0001037580A UY 37580 A UY37580 A UY 37580A UY 37580 A UY37580 A UY 37580A
Authority
UY
Uruguay
Prior art keywords
activity
inhibit
lrrk2
cinasa
new compounds
Prior art date
Application number
UY0001037580A
Other languages
English (en)
Inventor
Feng Ren
Yingxia Sang
Baowei Zhao
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY37580A publication Critical patent/UY37580A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos novedosos que inhiben la actividad de cinasa LRRK2, procesos para su preparación, a composiciones que los contienen y a su uso en el tratamiento de o la prevención de enfermedades asociadas a o caracterizadas por la actividad de cinasa LRRK2, por ejemplo, enfermedad de Parkinson, enfermedad de Alzheimer y esclerosis lateral amiotrófica (ELA).
UY0001037580A 2017-01-25 2018-01-23 Compuestos novedosos que inhiben la actividad de cinasa lrrk2 UY37580A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2017072590 2017-01-25

Publications (1)

Publication Number Publication Date
UY37580A true UY37580A (es) 2018-08-31

Family

ID=62978028

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037580A UY37580A (es) 2017-01-25 2018-01-23 Compuestos novedosos que inhiben la actividad de cinasa lrrk2

Country Status (10)

Country Link
US (1) US20210130339A1 (es)
EP (1) EP3573976A4 (es)
JP (1) JP2020505399A (es)
CN (1) CN110402247A (es)
AR (1) AR110769A1 (es)
BR (1) BR112019015273A2 (es)
CA (1) CA3050152A1 (es)
TW (1) TW201841908A (es)
UY (1) UY37580A (es)
WO (1) WO2018137573A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109897027B (zh) * 2019-04-28 2021-11-02 梯尔希（南京）药物研发有限公司 一种3-羟基地氯雷他定代谢物的合成方法
WO2020247298A2 (en) 2019-06-06 2020-12-10 Merck Sharp & Dohme Corp. 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US11427558B1 (en) 2019-07-11 2022-08-30 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
CN113185481A (zh) * 2021-04-07 2021-07-30 上海大学 四氢呋喃-3-酮的合成方法
AR127470A1 (es) 2021-10-27 2024-01-31 H Lundbeck As Inhibidores de lrrk2
EP4519255A1 (en) * 2022-05-02 2025-03-12 AcuraStem Incorporated Pikfyve kinase inhibitors
US11958865B1 (en) 2022-09-15 2024-04-16 H. Lundbeck A/S Leucine-rich repeat kinase 2 (LRRK2) inhibitors
WO2025201511A1 (zh) * 2024-03-29 2025-10-02 上海京新生物医药有限公司 吲唑衍生物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468729B1 (en) * 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
US20110130384A1 (en) * 2008-06-25 2011-06-02 Takeda Pharmaceutical Company Limited Amide compound
TW201512189A (zh) * 2013-04-16 2015-04-01 Gruenenthal Chemie 新型被取代之嘧啶縮合化合物
US10954240B2 (en) * 2014-09-03 2021-03-23 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
KR20180030201A (ko) * 2015-07-23 2018-03-21 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물

Also Published As

Publication number Publication date
US20210130339A1 (en) 2021-05-06
CA3050152A1 (en) 2018-08-02
JP2020505399A (ja) 2020-02-20
WO2018137573A1 (en) 2018-08-02
EP3573976A4 (en) 2020-09-30
EP3573976A1 (en) 2019-12-04
TW201841908A (zh) 2018-12-01
CN110402247A (zh) 2019-11-01
AR110769A1 (es) 2019-05-02
BR112019015273A2 (pt) 2020-04-14

Similar Documents

Publication Publication Date Title
UY37808A (es) Nuevos compuestos que inhiben la actividad quinasa de la lrrk2
DOP2016000195A (es) Compuestos
UY37580A (es) Compuestos novedosos que inhiben la actividad de cinasa lrrk2
BR112018001303A2 (pt) ?compostos?
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
CO2017011851A2 (es) Compuestos novedosos
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
BR112018074185A2 (pt) 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas
BR112016005881A2 (pt) composto, composição farmacêutica e uso do composto
BR112018003264A2 (pt) conjugados de aldeído e usos dos mesmos
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
UY37606A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY35628A (es) ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?.
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
BR112018010564A2 (pt) composições farmacêuticas compreendendo levodopa amida e usos das mesmas
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
MX2018011453A (es) Moduladores alostericos de receptores de acetilcolina nicotinicos.
MX2021003905A (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7